Pharma Giant Looking for New Diseases to Treat with Drug Linked to Suicide

By Martha Rosenberg, AlterNet. Posted February 17, 2009.

Many are outraged that Eli Lilly gave nonprofits $3.9 million in grants last year for medical courses to "educate" doctors about the pain-and-fatigue ailment fibromyalgia--more than it spent for diabetes and Alzheimer's which people already know they have. 

But finding new diseases to justify a drug's existence is the normal way pharma operates. 

Especially Lilly who agreed to pay $1.42 billion for illegal marketing of its anti-psychotic Zyprexa last month--$615 million for criminally promoting it for dementia--another $62 million to 32 states for illegal pediatric marketing and agreed to resolve Medicaid fraud investigations into "rebates" at the same time. (And how was your year?) 

And whose diabetes treatment Byetta is tanking since reports last summer of six deaths, at least two from pancreatitis. 

But Lilly's fibromyalgia-fighting drug, Cymbalta (duloxetine)--its second best seller after Zyprexa--is anything but normal. 

Starting with the death of 19-year-old Cymbalta test subject Traci Johnson in 2004--who  hanged herself in the Lilly Clinic in Indianapolis and had no history of mental problems--it has been beset by reports of baffling, rapid, unprovoked, and out of character suicides. 

A 37-year-old man described in the Feb. 2008 Journal of Clinical Psychopharmacology with a stable marriage and employment and no history of mental problems tried to kill himself with carbon monoxide two months after taking Cymbalta for back pain. "The patient was unable to state exactly why he wanted to commit suicide," write the four physician authors all with the Department of Psychiatry and Behavioral Sciences at the University of Kansas Medical Center who note he returned to normal when the drug was stopped. 

A 63-year-old man with no history of suicide attempts or ideation was similarly "unable to explain why he was having thoughts of wanting to die," say the authors after becoming suicidal two weeks after being put on Cymbalta for fatigue, insomnia and sadness. 

Last January, a Texas man prescribed Cymbalta for peripheral neuropathy because of a job that required him to be on his feet all day with no history mental problems "had a normal day at work, drove home, said he was going to grab a sandwich to his wife, and went and shot himself," his family wrote a reporter. 

In Feb. 2007, a 19-year-old Wisconsin college student recently put on Cymbalta "checked out books for a paper he was to write over the weekend," emailed his resume "to see if he could get a spot on Obama's team for the summer" and "then hung himself from his loft bed in his dorm," writes his family. One month earlier, a 21-year old Midwest college student, recently put on Cymbalta, took his own life three minutes after speaking to his family while driving home and sounding fine, the family wrote a reporter. 

Nor are incomprehensible and abrupt suicide attempts on Cymbalta a US phenomenon. 

See more stories tagged with: big pharma, cymbalta, lily

Martha Rosenberg is a columnist and cartoonist who frequently writes about the impact of the pharmaceutical, food and gun industries on public health. A former medical copywriter, her work has appeared in the Boston Globe, San Francisco Chronicle, Los Angeles Times and Chicago Tribune, as well as on the BBC and in the original National Lampoon.

Liked this story? Get top stories in your inbox each week from Health and Wellness! Sign up now »